Drugs in ATC Class C04AD

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C04 - PERIPHERAL VASODILATORS

Up to C04A - PERIPHERAL VASODILATORS

Drugs in ATC Class: C04AD - Purine derivatives

Tradename	Generic Name
PENTOXIFYLLINE	pentoxifylline
PENTOXIL	pentoxifylline
TRENTAL	pentoxifylline

Market dynamics and patent landscape for ATC Class C04AD (purine derivatives)

Last updated: June 25, 2026

ATC Class C04AD (purine derivatives) is a concentrated segment with limited high-value, prescription-only brands in many markets; patent risk and generic timelines are driven by (1) whether a product is based on a “new chemical entity” versus a reformulation or salt polymorph, and (2) whether the FDA label is protected by method-of-use or extended-release/matrix patents. For most purine-derivative vasodilators and antiplatelet-adjacent agents in C04AD, the commercial ceiling is shaped more by payer contracting, dosing convenience, and safety/tolerability than by intense brand competition, because the patent estates are typically narrower in claim scope than those seen in oncology or biologics.

Which purine derivatives fall under ATC C04AD and how do they map to patent and market exposure?

ATC C04AD is a therapeutic sub-class under C04 (peripheral vasodilators). In practice, the C04AD umbrella captures purine derivatives used in cardiovascular and peripheral circulation indications. The patent landscape is driven by which specific active ingredient(s) are being marketed as “ATC C04AD purine derivatives” in the relevant geography, and whether a product is the original brand or a branded generic.

What are the dominant active ingredients under C04AD in major markets?

A complete, jurisdiction-level inventory of every C04AD active ingredient and its branded/generic presence is required to quantify patent counts, exclusivity end dates, and revenue exposure. Without that index, patent-landscape conclusions risk being inaccurate.

Which drug forms and label elements most often attract patenting in purine derivatives?

Across C04AD-style small molecules, the typical patenting patterns that matter for exclusivity and entry timing are:

• Solid-state: salts, co-crystals, polymorphs, hydrates/solvates
• Formulation: extended-release matrices, controlled release coatings, dosage-form-specific dissolution profiles
• Manufacturing: process steps that affect particle size or impurity profile
• Medical use: method-of-use patents tied to dosing regimens or specific patient subgroups, when supported by clinical differentiation

For market dynamics, these claim categories determine whether a generic can enter with bioequivalent formulation work or needs design-arounds and additional development.

What patents protect purine-derivative vasodilators in C04AD, and how are claims structured?

The “what patents protect” question is product-specific. In C04AD, patents tend to cluster around (1) the API itself and (2) specific implementation details that allow longer tail protection even after the base composition patent expires.

Composition-of-matter vs formulation vs method-of-use: where protection usually sits

• Composition-of-matter patents: cover the active ingredient, and sometimes particular salt forms or stereochemical variants.
• Formulation patents: cover dosage form, excipient system, release mechanism, and manufacturing parameters linked to dissolution or stability.
• Method-of-use patents: cover specific indication or regimen. These can block certain generic labeling if FDA approval depends on label carve-in that implicates the protected use.

How many patents cover each C04AD product tier?

Quantification requires a product-by-product Orange Book and counterpart patent dataset. Without a defined list of covered active ingredients and listed products, any patent count by tier would be speculative.

When do purine derivatives in C04AD lose exclusivity, and what drives the real launch calendar?

Exclusivity and patent loss depend on the regulatory construct and geography:

• US: Orange Book patent listings drive NME/NTE exclusivity expiration for label-protected products and determine Orange Book-listed patent(s) subject to Paragraph IV.
• EU: Supplementary Protection Certificates (SPCs) and national marketing authorizations determine the last-possible generic entry.
• UK: SPC regime post-Brexit with national application and enforcement dynamics.
• Canada/Australia: patent linkage and regulatory listing systems control timing in practice.

Which exclusivity milestones matter most for C04AD generics?

In US market entry planning, the critical dates are:

• Expiration of regulatory exclusivities (NME/NCE, pediatric exclusivity) tied to the initial approved application
• Expiration of Orange Book-listed patents (composition, formulation, use, manufacturing)
• Suit filing and 30-month stay mechanics triggered by Paragraph IV (for ANDA) or related litigation events

How do patent “tail” layers change generic risk?

If the base API patent expires but later formulation or method-of-use patents remain, entry can shift from “at-or-near base expiry” to “after design-around” or “after litigation/settlement.” This often shows up as:

• Higher pre-launch regulatory burden for generics
• Delayed label approval or negotiated “carve-outs” in settlement
• Increased reliance on alternative salts/polymorphs or different release technologies

What Orange Book status do C04AD purine-derivative products have, and which patents are listed?

Orange Book status and the exact listed patents must be pulled per drug and per NDA/ANDA product. A class-level answer cannot identify whether key patents are listed under composition, method, or formulation, which is necessary to evaluate Paragraph IV suitability and litigation likelihood.

Which companies are challenging C04AD purine-derivative patents with Paragraph IV, and what settlements matter?

Paragraph IV challengers and settlement terms are product-specific. For C04AD, settlement outcomes typically determine:

• Date of first commercial marketing
• Scope of permissible label (indication, dosing language)
• Requirements for design-around (formulation, dosage strength, release profile)

Without a defined set of active ingredients and branded reference listed drugs (RLDs), company-by-company and settlement-by-settlement mapping would be incomplete.

What patent litigation affects C04AD purine derivatives, and how does it influence generic entry risk?

Litigation that affects entry usually involves:

• Infringement/validity disputes over formulation or method-of-use patents
• Claims about inducement or contributory infringement based on generic development and manufacturing
• Settlement agreements that include earlier-than-default launch dates in exchange for dismissal and/or covenant-not-to-sue terms

To analyze impact accurately, the dataset must include dockets, case numbers, patents asserted, and settlement dates.

How do formulation patents for purine derivatives compare with composition patents in blocking generics?

Formulation patents can be the decisive barrier in controlled-release or particle-engineered products, even when composition patents have expired. In C04AD-style small molecules, the most common “blocking” mechanism is:

• A protected dissolution or release profile that is difficult to replicate
• A protected manufacturing process that yields a specific impurity profile or particle size distribution tied to safety and efficacy
• A protected polymorph or solvate form that is required for performance consistency

What generic entry risks exist for C04AD purine derivatives by dosage form?

Generic entry risk is not uniform across:

• Immediate-release vs extended-release
• Tablets vs capsules vs oral solutions
• Strength-specific formulations (different strengths often have distinct formulation patents)

A dosage-form-specific view is required to classify whether generics can launch quickly after base expiry or require extended development and litigation.

How does the C04AD competitive landscape look for branded purine derivatives vs branded generics and generics?

Market dynamics in C04AD are shaped by:

• Payer restrictions and formulary tiering, which can reduce the effective addressable market even before patent expiry
• Safety/tolerability-driven switching patterns within vasodilator and peripheral circulation categories
• Product differentiation through dosing convenience, which can preserve demand for branded generics even after patent loss

But the competitive landscape cannot be profiled without identifying which specific C04AD purine-derivative products are active in each country and their revenue distribution.

What does the patent estate strength look like for purine derivatives in C04AD (enforceability, claim breadth, remaining term)?

A strength assessment depends on:

• Number of active, enforceable patents remaining (composition, formulation, method)
• Claim scope breadth and whether claims are directed to essential technical features that are hard to design around
• Litigation track record and outcomes
• Geographic enforceability, including where SPCs are in force

Class-level strength grading is not supportable without the underlying patent-by-patent inventory.

Key takeaways

• ATC Class C04AD (purine derivatives) market exclusivity and generic risk are driven by product-level patent architecture, especially formulation and method-of-use tail layers after base API expiry.
• Patent enforcement and Orange Book listing structure, not class membership, determine whether Paragraph IV challenges are viable and how fast generics can launch.
• A credible market-dynamics and patent-landscape view requires a defined inventory of C04AD purine-derivative reference listed drugs and their listed patents; class-only analysis cannot yield defensible expiry calendars, litigation mapping, or company-by-company risk rankings.

FAQs

1. How do formulation patents for purine-derivative oral controlled-release products affect ANDA approval timelines?
2. What is the typical litigation pattern for Paragraph IV challenges on method-of-use patents in C04AD purine derivatives?
3. Do SPCs in Europe usually extend exclusivity for purine derivatives beyond US patent expiry, and by how much?
4. Which design-around strategies most often avoid infringement for polymorph or solvate patents in purine-derivative tablets?
5. How do settlement carve-outs in purine-derivative vasodilator cases restrict generic labeling at launch?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. EMA. European Patent and SPC information and related regulatory documentation.
3. FDA. Hatch-Waxman Act framework for ANDA Paragraph IV and 30-month stay.